Document:

<PAGE>

                                                                   EXHIBIT 10.16

                                 AMENDMENT NO. 3

                                       TO

              THE DEVELOPMENT AND MANUFACTURING SERVICES AGREEMENT

                              DATED 08 JANUARY 2004

                                     BETWEEN

                               LONZA BIOLOGICS PLC

                                       AND

                          TRUBION PHARMACEUTICALS, INC.

Re:

Schedule 2 - Services

Updated Stages

     Stage 11 Reference Standard Characterisation

Schedule 2
New Stages

           Add Stage 19   ***
           Add Stage 20   ***
           Add Stage 21   ***

Schedule 3

     Price and Payment

                                                          CONFIDENTIAL TREATMENT

<PAGE>

THIS AMENDMENT is made the 7th day of February, 2005

BETWEEN

1.   LONZA BIOLOGICS PLC, the registered office of which is at 228 Bath Road,
     Slough, Berkshire SL1 4DX, England ("LB") and

2.   TRUBION PHARMACEUTICALS, INC., of 2401 4th Avenue, Suite 1050, Seattle, WA
     98121, USA (herein after referred to as the "Customer").

WHEREAS

A.   Customer and LB entered into a development and manufacturing services
     agreement dated 08 January 2004 ("the Agreement"), under which LB is
     required to perform Services relating to the Cell Line and the Product, as
     further described in the Agreement, and

B.   Customer would like LB to perform additional services under the Agreement,
     and

C.   LB is prepared to perform the additional services, and the parties wish to
     amend the Agreement accordingly.

NOW THEREFORE it is agreed as follows:

1. Schedule 2 of the Agreement shall be amended to revise Stage 11 (Reference
Standard Characterisation),as follows:

                                   SCHEDULE 2

Stage 11 of Schedule 2 shall now read in its entirety as follows:

STAGE 11 REFERENCE STANDARD CHARACTERISATION

     11.1 OBJECTIVES

          ***

     11.2 ACTIVITIES

          ***

     11.3 DELIVERABLES

          11.3.1 A report of activities carried out under this Stage 11 as
detailed in activity 11.2.4

                                                          CONFIDENTIAL TREATMENT

<PAGE>

     11.4 TIMESCALE

     This Stage will commence as soon as Product is available from Stage 6 and
will be complete on issue of the final report of activities (activity 11.2.6)
and it is estimated that this shall be issued *** from the issue of protocol.

                                                          CONFIDENTIAL TREATMENT

                                       -2-

<PAGE>

     2. Schedule 2 of the Agreement shall be amended to include the following
additional stages, Stage 19 (Stability Study (*** Pilot Material)), Stage 20
(Product Characterisation *** Pilot and *** cGMP Material) and Stage 21
(Shipping Trial):

STAGE 19 ***

     19.1 OBJECTIVES

     ***

     19.2 ACTIVITIES

     ***

     19.3 DELIVERABLES

          19.3.1 A summary report of activities to the Customer.

     19.4 TIMESCALE

     This Stage may commence as soon as Product is available and will be
complete upon issue of the summary report of activities.

     It is estimated that the summary report will be available within *** from
commencement.

STAGE 20 ***

     20.1 OBJECTIVES

          ***

     20.2 ACTIVITIES

          ***

     20.3 DELIVERABLES

          20.3.1 Report for the *** study.

          20.3.2 Data summaries of *** study.

          20.3.3 Report for the *** study.

          20.3.4 Audited data table summaries of ***from the *** study.

                                                          CONFIDENTIAL TREATMENT

                                       -3-

<PAGE>

     20.4 TIMESCALE

     This Stage may commence as soon as Product is available and will be
complete upon issue of the final reports of activities.

     It is estimated that the audited data table summaries will be available
within *** from commencement.

     It is estimated that both final reports will be issued *** from
commencement.

                                                          CONFIDENTIAL TREATMENT

                                       -4-

<PAGE>

STAGE 21 ***

     21.1 OBJECTIVES

          ***

     21.2 ACTIVITIES

          ***

     21.3 DELIVERABLES

          21.3.1 A non-cGMP report of activities, analysis and results of the
               study.

     21.4 TIMESCALE

     This Stage may commence upon signature of this Amendment 3 and will be
complete upon issue of the (non-cGMP) report of activities.

     It is estimated that the (non-cGMP) report will be available within ***
month from commencement.

                                                          CONFIDENTIAL TREATMENT

                                       -5-

<PAGE>

     3. Schedule 3 of the Agreement shall be amended by the addition of the
following provisions in respect of the additional Stages contained in this
Amendment No. 3;

                                   SCHEDULE 3

                           Price and Terms of Payment

1. Price

     In consideration for LB carrying out the updated Services described in
Stage 11 and the new Services as described in Stage 19, Stage 20 and Stage 21 as
detailed in Schedule 2 the Customer shall pay LB as follows:

     ***
     *** Reference Standard Characterisation ***
     ***

2. Payment

     Payment by the Customer of the Price for each Stage -shall be made against
LB's invoices as follows:

2.1    For Stage 11
       100% upon completion of Stage 11.

2.2    For Stage 19
       100% upon completion of Stage 19.

2.2    For Stage 20
       100% upon completion of Stage 20.

2.2    For Stage 21
       100% upon completion of Stage 21.

3. Any capitalized term used but not defined in this Amendment No. 3 shall
have the meaning given in the Agreement.

4. Save as herein provided all other terms and conditions of the Agreement
shall remain in full force and effect.

                                                          CONFIDENTIAL TREATMENT

                                       -6-

<PAGE>

     IN WITNESS WHEREOF the parties have caused this Amendment No. 3 to be
executed by their duly authorised representatives thereunto as of the day and
year first above written.

Signed for and on behalf of
LONZA BIOLOGICS PLC                /s/ Rene Imwinkleried
                                   ---------------------------------------------
                                   Director
                                   Title

Signed for and on behalf of
TRUBION PHARMACEUTICALS, INC.      /s/ Kendall Mohler
                                   ---------------------------------------------
                                   Senior Vice President, Research & Development

                                                          CONFIDENTIAL TREATMENT

                                       -7-<PAGE>

                                                                   EXHIBIT 10.17

                                                                           Lonza

                                 AMENDMENT NO. 4

                                       TO

              THE DEVELOPMENT AND MANUFACTURING SERVICES AGREEMENT

                              DATED 08 JANUARY 2004

                                     BETWEEN

                               LONZA BIOLOGICS PLC

                                       AND

                          TRUBION PHARMACEUTICALS, INC.

Re:

Schedule 1

Schedule 2

     Stage 22 ***.

Schedule 3

     Price and Payment

                                                          CONFIDENTIAL TREATMENT

<PAGE>

                                                                           Lonza

THIS AMENDMENT is made the 4th day of January, 2005

BETWEEN

1. LONZA BIOLOGICS PLC, the registered office of which is at 228 Bath Road,
Slough, Berkshire SL1 4DX, England ("LB") and

2. TRUBION PHARMACEUTICALS, INC., 2401 4th Avenue, Suite 1050, Seattle, WA
98121, USA. ("Customer")

WHEREAS

A.   Customer and LB entered into an agreement dated 08 January 2004 as amended
     ("The Agreement"), under which LB is required to perform Services relating
     to the Cell line and Product described, and

B.   Customer would like LB to carry out additional activities under the
     Agreement, and

C.   LB is prepared to perform the additional activities.

NOW THEREFORE it is agreed hereby by the parties to amend the Agreement and
perform additional services as follows:

                                                          CONFIDENTIAL TREATMENT

<PAGE>

                                                                           Lonza

1. Schedule 2 of the Agreement shall be amended to include the following
additional stage:

                                   SCHEDULE 2

STAGE 22 ***

     22.1 OBJECTIVE

          ***

     22.2 ACTIVITIES

          ***

     22.3 TIMESCALE

     This Stage commenced ***. This Stage will be complete on issue of all the
Protocols and Reports mentioned above in section 22.2.1.

                                                          CONFIDENTIAL TREATMENT

                                       -2-

<PAGE>

2. Schedule 3 of the Agreement shall be amended by the addition of the following
provisions in respect of the additional Stages contained in this Amendment no.
4:

                                   SCHEDULE 3

                           Price and Terms of Payment

1.   Price

     In consideration for LB carrying out the Services as detailed in Schedule 2
the Customer shall pay LB as follows:

     ***

2.   Payment

     Payment by the Customer of the Price for each Stage shall be made against
LB's invoices as follows:

     2.1  For Stage 22

          *** upon commencement of Stage 22.

          *** upon completion of Stage 22.

     Save as herein provided all other terms and conditions of the Agreement
shall remain in full force and effect.

     IN WITNESS WHEREOF the parties have caused this Amendment No. 4 to be
executed by their representatives thereunto duly authorised as of the day and
year first written.

Signed for and on behalf of
LONZA BIOLOGICS PLC                     /s/ Rene Imwinkleried
                                        ----------------------------------------
                                        Director
                                        Title

Signed for and on behalf of
TRUBION PHARMACEUTICALS INC.            /s/ Peter A. Thompson
                                        ----------------------------------------
                                        President & CEO
                                        Title

                                                          CONFIDENTIAL TREATMENT

                                       -3-

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00110-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00110-of-00352.parquet"}]]